The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. (Q37166798)
Jump to navigation
Jump to search
scientific article published on 05 July 2012
Language | Label | Description | Also known as |
---|---|---|---|
English | The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. |
scientific article published on 05 July 2012 |
Statements
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects (English)
M A Hurchla
A Garcia-Gomez
M C Hornick
A Li
J F Blanco
L Collins
C J Kirk
D Piwnica-Worms
R Vij
M H Tomasson
K N Weilbaecher
1 reference
1 reference
1 reference
1 reference
1 reference